慢性乙型肝炎合并非酒精性脂肪性肝病与肝细胞癌

doi:10.3969/j.issn.1672-5069.2023.03.037

摘要/Abstract

摘要： 随着肥胖、糖尿病患病率的升高,非酒精性脂肪性肝病(NAFLD)发病率逐渐升高。在慢性乙型肝炎(CHB)患者中,合并NAFLD的患者亦越来越多。慢性HBV感染和NAFLD均是导致肝细胞癌(HCC)的病因。CHB合并NAFLD可能增加HCC的发生风险。本文主要从CHB合并NAFLD与HCC的发生机制及其防控管理相关内容做一综述。

关键词: 肝细胞癌, 慢性乙型肝炎, 非酒精性脂肪性肝病, 发病机制, 管理

Abstract: With the increasing prevalence of obesity and diabetes, the incidence of nonalcoholic fatty liver diseases(NAFLD)has gradually increased. More and more patients with chronic hepatitis B (CHB) are complicated with NAFLD. The chronic HBV infection and NAFLD are both causes of hepatocellular carcinoma(HCC), and the patients with CHB and NAFLD might have the increased risk of HCC. In this article, we review the hepatocarcinogenesis, prevention and control management of patients with CHB and NAFLD, and patients with HCC.

Key words: Hepatocellular carcinoma, Hepatitis B, Nonalcoholic fatty liver diseases, Pathogenesis, Management

苏佩华, 宋枚芳, 赵彩彦. 慢性乙型肝炎合并非酒精性脂肪性肝病与肝细胞癌[J]. 实用肝脏病杂志, 2023, 26(3): 445-448.

Su Peihua, Song Meifang, Zhao Caiyan. Is the incidence of hepatocellular carcinoma increased in patients with chronic hepatitis B and nonalcoholic fatty liver diseases?[J]. Journal of Practical Hepatology, 2023, 26(3): 445-448.

参考文献

[1] Hui RWH, Seto WK, Cheung KS, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study. J Viral Hepat, 2018, 25(1): 97-104.
[2] Yang J, Chen X, Zhang H, et al. HBV genotype C strains with spontaneous YMDD mutations may be a risk factor for hepatocellular carcinoma. J Med Virol, 2014, 86(6): 913-917.
[3] Kao JH, Chen PJ, Lai MY, et al. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology, 2003, 124(2): 327-334.
[4] Park YM, Jang JW, Yoo SH, et al. Combinations of eight key mutations in the X/preC region and genomic activity of hepatitis B virus are associated with hepatocellular carcinoma. J Viral Hepat, 2014, 21(3): 171-177.
[5] Zhang Y, Yan Q, Gong L, et al. C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism. Oncogene, 2021, 40(6): 1147-1161.
[6] Mao X, Tey SK, Ko FCF, et al. C-terminal truncated HBx protein activates caveolin-1/LRP6/β-catenin/FRMD5 axis in promoting hepatocarcinogenesis. Cancer Lett, 2019, 444: 60-69.
[7] Toh ST, Jin Y, Liu L, et al. Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients reveals enriched integration events, structural alterations and sequence variations. Carcinogenesis, 2013, 34(4): 787-798.
[8] Jiang Y, Han Q, Zhao H, et al. The mechanisms of HBV-induced hepatocellular carcinoma. J Hepatocell Carcinoma, 2021, 8: 435-450.
[9] Cougot D, Wu Y, Cairo S, et al. Correction: The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription. J Biol Chem, 2020, 295(9): 2888.
[10] Martin-Lluesma S, Schaeffer C, Robert EI, et al. Hepatitis B virus X protein affects S phase progression leading to chromosome segregation defects by binding to damaged DNA binding protein 1. Hepatology, 2008, 48(5): 1467-1476.
[11] Liu H, Shi W, Luan F, et al. Hepatitis B virus X protein upregulates transcriptional activation of human telomerase reverse transcriptase. Virus genes, 2010, 40(2): 174-182.
[12] Mohammadizad H, Shahbazi M, Hasanjani Roushan MR, et al. TIM-3 as a marker of exhaustion in CD8(+) T cells of active chronic hepatitis B patients. Microb Pathog, 2019, 128: 323-328.
[13] Lim CJ, Lee YH, Pan L, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut, 2019, 68(5): 916-927.
[14] Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology, 2007, 132(7): 2328-2339.
[15] Peppa D, Micco L, Javaid A, et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog, 2010, 6(12): e1001227.
[16] De Minicis S, Agostinelli L, Rychlicki C, et al. HCC development is associated to peripheral insulin resistance in a mouse model of NASH. PloS One, 2014, 9(5): e97136.
[17] Kudo Y, Tanaka Y, Tateishi K, et al. Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway. J Hepatol, 2011, 55(6): 1400-1408.
[18] Chettouh H, Lequoy M, Fartoux L, et al. Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma. Liver Int, 2015, 35(10): 2203-2217.
[19] Sorrentino P, D'angelo S, Ferbo U, et al. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol, 2009, 50(2): 351-357.
[20] He G, Karin M. NF-κB and STAT3-key players in liver inflammation and cancer. Cell Res, 2011, 21(1): 159-168.
[21] Ding J, Zhao J, Huan L, et al. Inflammation-induced long intergenic noncoding RNA (LINC00665) increases malignancy through activating the double-stranded RNA-activated protein kinase/nuclear factor Kappa B pathway in hepatocellular carcinoma. Hepatology, 2020, 72(5): 1666-1681.
[22] Huang H, Zhang J, Ling F, et al. Leptin receptor (LEPR) promotes proliferation, migration, and invasion and inhibits apoptosis in hepatocellular carcinoma by regulating ANXA7. Cancer Cell Int, 2021, 21(1): 4.
[23] Stefanou N, Papanikolaou V, Furukawa Y, et al. Leptin as a critical regulator of hepatocellular carcinoma development through modulation of human telomerase reverse transcriptase. BMC cancer, 2010, 10: 442.
[24] Sharma D, Wang J, Fu PP, et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology, 2010, 52(5): 1713-1722.
[25] Xing SQ, Zhang CG, Yuan JF, et al. Adiponectin induces apoptosis in hepatocellular carcinoma through differential modulation of thioredoxin proteins. Biochem Pharmacol, 2015, 93(2): 221-231.
[26] Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature, 2016, 531(7593): 253-257.
[27] Wolf MJ, Adili A, Piotrowitz K, et al. Metabolic activation of intrahepatic CD8⁺ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer cell, 2014, 26(4): 549-564.
[28] Chan AW, Wong GL, Chan HY, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol, 2017, 32(3): 667-676.
[29] Choi HSJ, Brouwer WP, Zanjir WMR, et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B. Hepatology, 2020, 71(2): 539-548.
[30] Pereira Tde A, Witek RP, Syn WK, et al. Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. Lab Invest, 2010, 90(12): 1690-1703.
[31] Rangwala F, Guy CD, Lu J, et al. Increased production of sonic Hedgehog by ballooned hepatocytes. J Pathol, 2011, 224(3): 401-410.
[32] Liang H, Liu Y, Jiang X, et al. Impact of hepatic steatosis on the antiviral effects of PEG-IFNα-2a in patients with chronic hepatitis B and the associated mechanism. Gastroenterol Res Pract, 2020, 2020: 1794769.
[33] Jin X, Chen YP, Yang YD, et al. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PloS One, 2012, 7(3): e34198.